Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.70 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.37 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.37 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.37 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2981069 | 0.85 | KMT2A (0.61) | KMT2ANPSR1TSHRSMN1; SMN2MAPT | |
| SCHEMBL9906306 | 0.85 | KMT2A (0.61) | KMT2ANPSR1TSHRSMN1; SMN2MAPT | |
| SCHEMBL2991760 | 0.83 | KMT2A (0.59) | KMT2ANPSR1TSHRSMN1; SMN2MAPT | |
| SCHEMBL8313919 | 0.83 | — | — | |
| SCHEMBL23861292 | 0.79 | KMT2A (0.84) | KMT2ANPSR1TSHRSMN1; SMN2MAPT | |
| SCHEMBL29043353 | 0.79 | KMT2A (0.84) | KMT2ANPSR1TSHRSMN1; SMN2MAPT | |
| SCHEMBL11015380 | 0.78 | KMT2A (0.81) | KMT2ANPSR1TSHRSMN1; SMN2ALDH1A1 | |
| SCHEMBL2731577 | 0.77 | KMT2A (0.52) | KMT2ANPSR1TSHRSMN1; SMN2MAPT | |
| Hydrochloric Acid SCHEMBL28457687 | 0.76 | KMT2A (0.41) | KMT2ANPSR1CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL2301129 | 0.76 | KMT2A (0.66) | KMT2ANPSR1TSHRSMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7999006-B2 | Anticancer agents; mitogen-activated protein kinases (MEK) | EXELIXIS, INC. (US) | 2011-08-16 | — | — | US | claimed |
| US-20080166359-A1 | Methods of using MEK inhibitors | EXELIXIS, INC. | 2008-07-10 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080166359-A1 | Methods of using MEK inhibitors | BRAF, NRAS, KRAS | KMT2A 669/4885NPSR1 4167/4885TSHR 3752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.